CNS drugs最新文献

筛选
英文 中文
Acknowledgement to Referees. 给推荐人的确认函。
IF 7 2区 医学
CNS drugs Pub Date : 2026-11-10 DOI: 10.1007/s40263-026-01347-z
{"title":"Acknowledgement to Referees.","authors":"","doi":"10.1007/s40263-026-01347-z","DOIUrl":"https://doi.org/10.1007/s40263-026-01347-z","url":null,"abstract":"","PeriodicalId":10508,"journal":{"name":"CNS drugs","volume":" ","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Toad Venom to Drug Development: The Clinical Pharmacology of Mebufotenin (5-MeO-DMT) in Treatment-Resistant Depression. 从蟾蜍毒液到药物开发:Mebufotenin (5-MeO-DMT)治疗难治性抑郁症的临床药理学。
IF 7 2区 医学
CNS drugs Pub Date : 2026-11-04 DOI: 10.1007/s40263-026-01346-0
Robert Likić, Igor Radanović, Deni Rkman, Sanja Brnić, Gabriel Jacobs, Geert Jan Groeneveld
{"title":"From Toad Venom to Drug Development: The Clinical Pharmacology of Mebufotenin (5-MeO-DMT) in Treatment-Resistant Depression.","authors":"Robert Likić, Igor Radanović, Deni Rkman, Sanja Brnić, Gabriel Jacobs, Geert Jan Groeneveld","doi":"10.1007/s40263-026-01346-0","DOIUrl":"https://doi.org/10.1007/s40263-026-01346-0","url":null,"abstract":"<p><p>Treatment-resistant depression affects about one-third of patients with major depressive disorder and remains a major unmet need. Mebufotenin (5-methoxy-N,N-dimethyltryptamine; 5-MeO-DMT), the principal psychoactive constituent of Incilius alvarius parotoid secretion and of several Amazonian plants, is a pharmacologically atypical serotonergic psychedelic in clinical development for this indication. This narrative review analyses its clinical pharmacology, drawing on a structured search of PubMed/MEDLINE, EMBASE, Scopus, ClinicalTrials.gov and grey literature through 15 August 2026, supplemented by regulatory and sponsor disclosures. Mebufotenin is a non-selective serotonin agonist with high affinity at 5-hydroxytryptamine receptor 1A (5-HT<sub>1A</sub>, Ki 3.0 nM) and markedly lower affinity at 5-HT<sub>2A</sub>, with reported selectivity spanning approximately 30-fold to 300-fold depending on whether the 5-HT<sub>2A</sub> receptor is agonist- or antagonist-labelled. Clearance is dominated by monoamine oxidase A; the cytochrome P450 2D6 (CYP2D6)-derived metabolite bufotenine has a receptor profile comparable to the parent compound rather than a distinct 5-HT<sub>2A</sub>-preferring one, and was below the limit of quantification in the only human study to measure it. In the pivotal phase 2b trial (GH001-TRD-201), inhaled GH001 produced a day 8 placebo-adjusted Montgomery-Åsberg Depression Rating Scale (MADRS) reduction of - 15.5 points (p < 0.001; d = - 2.0) and day 8 remission in 23/40 (57.5%) versus 0/41 (0%) with placebo, with 20/23 (87.0%) day 8 remitters in remission at 6 months under as-needed retreatment and no serious treatment-related adverse events. Median psychoactive duration was 9.0-14.0 min across doses, and 97.5% of patients were discharge-ready within 1 h. GH001 has been studied without protocol-mandated psychotherapy, although this does not establish that psychological support is unnecessary. Evidence rests principally on a single randomised trial, and replication in larger, more diverse phase 3 studies with formal blinding-integrity assessment is required.</p>","PeriodicalId":10508,"journal":{"name":"CNS drugs","volume":" ","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of an Early Aggressive Lipid-Lowering Strategy Using Triple Therapy After Mechanical Thrombectomy. 机械取栓后三联治疗早期积极降脂策略的有效性和安全性。
IF 7 2区 医学
CNS drugs Pub Date : 2026-11-01 Epub Date: 2026-08-03 DOI: 10.1007/s40263-026-01321-9
Ho Geol Woo, Jaeyu Park, Tae-Jin Song, Mi-Yeon Eun, Heejung Mo, Hee-Kwon Park
{"title":"Efficacy and Safety of an Early Aggressive Lipid-Lowering Strategy Using Triple Therapy After Mechanical Thrombectomy.","authors":"Ho Geol Woo, Jaeyu Park, Tae-Jin Song, Mi-Yeon Eun, Heejung Mo, Hee-Kwon Park","doi":"10.1007/s40263-026-01321-9","DOIUrl":"10.1007/s40263-026-01321-9","url":null,"abstract":"<p><strong>Background: </strong>Current guidelines recommend initial high-intensity statin monotherapy and \"the wait and watch paradigm,\" even in patients with acute ischemic stroke (AIS). However, newer lipid-lowering therapies allow aggressive low-density lipoprotein cholesterol (LDL-C) reduction without drug class restriction. The effectiveness of triple therapy (early aggressive strategy) comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, ezetimibe, and a high-intensity statin after endovascular thrombectomy (EVT) for emergent large vessel occlusion (ELVO) remains uncertain.</p><p><strong>Methods: </strong>We retrospectively analyzed patients with AIS due to ELVO who underwent successful EVT at four comprehensive stroke centers between January 2021 and December 2024. Patients were classified into triple therapy or high-intensity statin monotherapy (standard therapy) and followed up for 90 days. Multivariable regression and propensity score matching were used.</p><p><strong>Results: </strong>Among 197 patients (mean age, 70.8 ± 12.1; 36.0% male), 55 received triple therapy. Baseline total cholesterol (TC) and LDL-C levels were comparable between groups. At both 4 and 12 weeks, the triple therapy group demonstrated significantly lower mean TC and LDL-C levels compared with the standard therapy group. Triple therapy was independently associated with a reduced risk of early neurological deterioration (adjusted odds ratio [aOR], 0.14; 95% confidence interval [CI], 0.03-0.81). In the subgroup of patients with ELVO due to large-artery atherosclerosis (LAA), triple therapy was further associated with a higher likelihood of functional independence at 90 days (aOR 9.30; 95% CI 1.86-46.56).</p><p><strong>Conclusions: </strong>Triple therapy achieved faster and greater LDL-C reduction and improved clinical outcomes following EVT, particularly among patients with AIS due to ELVO from LAA.</p>","PeriodicalId":10508,"journal":{"name":"CNS drugs","volume":" ","pages":"1513-1526"},"PeriodicalIF":7.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms. 单极情绪障碍的下一代药物治疗:一篇关于跨多种机制的II/III期药物开发的重要文章。
IF 7 2区 医学
CNS drugs Pub Date : 2026-11-01 Epub Date: 2026-08-26 DOI: 10.1007/s40263-026-01330-8
Alana King, Morgan Hardy, Taeho Greg Rhee, Samuel T Wilkinson
{"title":"Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.","authors":"Alana King, Morgan Hardy, Taeho Greg Rhee, Samuel T Wilkinson","doi":"10.1007/s40263-026-01330-8","DOIUrl":"10.1007/s40263-026-01330-8","url":null,"abstract":"<p><p>Despite the wide prevalence of mood disorders globally, there is a substantial unmet need for effective, mechanistically distinct treatments. Given that approximately 30% of individuals do not display adequate response to standard antidepressant therapies, the past 15 years have seen a shift away from traditional monoaminergic approaches toward glutamatergic and other novel mechanisms. Following the US Food and Drug Administration (FDA) approval of esketamine and brexanolone in 2019, industry investment in therapeutics with novel mechanisms for mood and anxiety disorders has expanded, catalyzing a new wave of innovative interventions. This review summarizes progress for unipolar mood disorders in four categories-glutamatergic/GABA modulators, ion channel modulators, psychedelics, and other potential therapeutic mechanisms-focusing on Phase II/III industry-sponsored US clinical trials active within the past 3 years. The drug names discussed are ALTO-100, ALTO-203, ALTO-207, ALTO-300, BHV-7000, BI-1569912, BPL-003, COMP360, DT120, ELE-101, GATE-251, GH001, GM-1020, GM-2505, HLP003, MK-1942, NBI-1065845, NBI-1070770, NV-5138, PIPE-307, SEP-363856, SPT-300, VLS-01, and XEN1101. The US Clinical Trials registry (clinicaltrials.gov), MEDLINE, conference proceedings, and company communications such as press releases were consulted to obtain up-to-date trial information and reported outcomes. Overall, the therapeutic landscape shows an expanding range of clinical compounds under active development; nonetheless, persistent challenges remain, including approaches to therapeutics where functional unblinding may occur, the ways in which to consider a novel conceptualization of occupancy-driven versus event-driven pharmacology, and the role of supporting psychotherapy.</p>","PeriodicalId":10508,"journal":{"name":"CNS drugs","volume":" ","pages":"1429-1444"},"PeriodicalIF":7.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148825653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials. 经批准的药物治疗物质使用障碍:系统综述和已完成的3期随机对照试验综述。
IF 7 2区 医学
CNS drugs Pub Date : 2026-11-01 Epub Date: 2026-09-23 DOI: 10.1007/s40263-026-01334-4
Itai Danovitch, Kyla Truman, Haze Brown, Macie Miller, Shaishav Shah, Jayant Totlani, Daniel N Kaidbay, Kaleab K Tessema, Zholi Minasyan, Waguih William IsHak, Samuel Miles, Robert N Pechnick
{"title":"Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials.","authors":"Itai Danovitch, Kyla Truman, Haze Brown, Macie Miller, Shaishav Shah, Jayant Totlani, Daniel N Kaidbay, Kaleab K Tessema, Zholi Minasyan, Waguih William IsHak, Samuel Miles, Robert N Pechnick","doi":"10.1007/s40263-026-01334-4","DOIUrl":"10.1007/s40263-026-01334-4","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background and objectives: &lt;/strong&gt;This umbrella review of systematic reviews, meta-analyses, and completed phase 3 randomized controlled trials (RCTs) over the past 10 years covers approved pharmacological treatments for substance use disorders (SUD) worldwide, providing clinicians and researchers with a detailed analysis of current pharmacotherapies and bridging the gap between evolving pharmacological interventions and clinical practice.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This PROSPERO-registered umbrella review used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Peer-reviewed systematic reviews were selected to include systematic reviews of RCTs and meta-analyses that examined approved medications for treatment, withdrawal management, or overdose reversal of SUD in all populations. Reviews published in peer-reviewed journals from 1 January 2016 to 1 January 2026, including medications that received worldwide approvals from World Health Organization (WHO)-listed Authorities plus those in the ten most populous countries were included. Reviews of preclinical studies and those not meeting systematic review standards or missing required data were excluded. We also included completed phase 3 SUD medications, including only RCTs with posted results from 2016 to 2026; preclinical studies and those with missing required data were excluded. We searched PubMed, MEDLINE, and the Cochrane Library databases for systematic reviews using keywords related to SUD. We also searched for phase 3 medications on the WHO International Clinical Trials Registry Platform. Risk of bias and methodological quality were assessed using the Risk if Bias in Systematic Reviews (ROBIS) and A Measurement Tool to Assess Systematic Reviews (AMSTAR-2) tools for systematic reviews and using the Cochrane risk of bias (RoB2) tool for phase 3 RCTs. Two independent reviewers conducted the selection process, resolving discrepancies through discussion, consultation with a third reviewer, and reaching consensus. The results were synthesized narratively and presented by each medication in summaries and tables.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Sixteen systematic reviews were reviewed, containing 371 RCTs (n = 131,965) and 62 observational studies (OS) (n = 229,225) examining 41 approved medications (with 25 distinct molecules) for SUD worldwide as of 1 January 2026: Eighty-six RCTs (n = 18,643) covering seven medications for alcohol use disorder (AUD), showed a reduction of risk of returning to any drinking ranging from 7 to 17% compared with placebo; three for alcohol withdrawal/intoxication. A total of 49 RCTs (n = 7804) and 21 OS (n = 155,111) covering 12 medications for opioid use disorder (OUD), showed that the highest abstinence rates ranged from 41 to 43% compared with 5% in placebo. Forty-one OS (n = 74,114) covering nine medications for opioid overdose reversal, with survival rates ranging from 92 to 98%; one for opioid withdrawal","PeriodicalId":10508,"journal":{"name":"CNS drugs","volume":" ","pages":"1481-1511"},"PeriodicalIF":7.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149030099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis. rozanolizumab: AChR或MuSK自身抗体阳性的全身性重症肌无力的综述
IF 7 2区 医学
CNS drugs Pub Date : 2026-11-01 Epub Date: 2026-09-30 DOI: 10.1007/s40263-026-01335-3
Aisling McGuigan, Hannah A Blair
{"title":"Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis.","authors":"Aisling McGuigan, Hannah A Blair","doi":"10.1007/s40263-026-01335-3","DOIUrl":"10.1007/s40263-026-01335-3","url":null,"abstract":"<p><p>Rozanolixizumab (rozanolixizumab-noli; RYSTIGGO<sup>®</sup>), a humanised immunoglobulin G4P monoclonal antibody, is a subcutaneously administered neonatal Fc receptor (FcRn) inhibitor approved for the treatment of both acetylcholine receptor (AChR) and muscle-specific kinase (MuSK) autoantibody-positive (Ab+) generalised myasthenia gravis (gMG) in adults. The pivotal, randomised, placebo-controlled phase III MycarinG trial demonstrated that a 6-week cycle of once-weekly rozanolixizumab ≈ 7 mg/kg or ≈ 10 mg/kg resulted in statistically significant and clinically meaningful improvements across all myasthenia gravis-specific scales assessed at day 43 versus placebo. Treatment benefits were rapid, sustained and consistent across repeated symptom-driven rozanolixizumab cycles. In a randomised, open-label, phase III crossover trial, self-administered rozanolixizumab improved MG symptoms regardless of whether manual push or infusion pump method was used. Rozanolixizumab was generally well tolerated with an acceptable safety profile; the most common adverse events were headache, diarrhoea, pyrexia and nausea. Thus, rozanolixizumab is an efficacious and generally well tolerated therapy for adults with AChR or MuSK Ab+ gMG, representing a convenient and valuable additional treatment option for these patients.</p>","PeriodicalId":10508,"journal":{"name":"CNS drugs","volume":" ","pages":"1547-1559"},"PeriodicalIF":7.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cognitive Side Effects of Antiseizure Medications in Adults with Epilepsy: An Update with a Focus on New Therapeutic Agents. 成人癫痫患者抗癫痫药物的认知副作用:新治疗药物的最新进展。
IF 7 2区 医学
CNS drugs Pub Date : 2026-11-01 Epub Date: 2026-09-09 DOI: 10.1007/s40263-026-01331-7
Marco Mula
{"title":"Cognitive Side Effects of Antiseizure Medications in Adults with Epilepsy: An Update with a Focus on New Therapeutic Agents.","authors":"Marco Mula","doi":"10.1007/s40263-026-01331-7","DOIUrl":"10.1007/s40263-026-01331-7","url":null,"abstract":"<p><p>Antiseizure medications (ASMs) are the mainstay of epilepsy treatment but may adversely affect cognitive functions, deepening the cognitive and psychosocial burden intrinsic to epilepsy. Cognitive side effects vary widely across drug classes, doses, treatment regimens, and individual susceptibility, typically affecting attention, processing speed, memory, language, and executive function. This narrative review provides an updated synthesis of the clinical evidence on the cognitive effects of ASMs, mostly in adults, building on a prior 2009 review and focusing on agents introduced into clinical practice since then. A literature search of PubMed identified studies published between January 2009 and December 2025, yielding data from randomised controlled trials, observational studies, meta-analyses, and systematic reviews. Overall, newer-generation ASMs, including rufinamide, lacosamide, brivaracetam, cannabidiol, fenfluramine, and ganaxolone, demonstrate generally favourable cognitive profiles when used at recommended doses, particularly in monotherapy or rational polytherapy. Eslicarbazepine and cenobamate may be associated with mild, dose-dependent cognitive effects, occurring only at the upper end of the recommended dose range. In contrast, old ASMs and certain second-generation agents, notably topiramate and zonisamide, remain consistently associated with higher cognitive risks. Special populations, including older adults and individuals with intellectual disabilities, are particularly vulnerable to cognitive adverse effects and benefit from agents with low interaction potential and benign neuropsychological profiles. Cognitive dysfunction in epilepsy is multifactorial, reflecting the interaction between disease-related neurobiological mechanisms and treatment effects. Optimal management requires balancing seizure control with cognitive preservation through individualised drug selection, cautious titration, and minimisation of polytherapy to achieve the best functional and quality-of-life outcomes.</p>","PeriodicalId":10508,"journal":{"name":"CNS drugs","volume":" ","pages":"1445-1458"},"PeriodicalIF":7.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bistromathics in Epilepsy and the Relativity of Numbers. 癫痫的生物数学与数的相对性。
IF 7 2区 医学
CNS drugs Pub Date : 2026-11-01 Epub Date: 2026-09-11 DOI: 10.1007/s40263-026-01336-2
Emilio Russo, Roberta Roberti, Eugen Trinka
{"title":"Bistromathics in Epilepsy and the Relativity of Numbers.","authors":"Emilio Russo, Roberta Roberti, Eugen Trinka","doi":"10.1007/s40263-026-01336-2","DOIUrl":"10.1007/s40263-026-01336-2","url":null,"abstract":"","PeriodicalId":10508,"journal":{"name":"CNS drugs","volume":" ","pages":"1421-1427"},"PeriodicalIF":7.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Candidate Clinico-Demographic Predictors or Moderators of Efficacy and Tolerability of Pharmacological Treatment in Attention-Deficit/Hyperactivity Disorder (ADHD): An Analysis of the MED-ADHD Repository of Randomised Controlled Trials. 注意缺陷/多动障碍(ADHD)药物治疗疗效和耐受性的候选临床人口学预测因子或调节因子:对MED-ADHD随机对照试验库的分析
IF 7 2区 医学
CNS drugs Pub Date : 2026-11-01 Epub Date: 2026-08-13 DOI: 10.1007/s40263-026-01323-7
Sulagna Roy, Guilherme Fusetto Veronesi, Sara Mannarini, Daniele Pirolo, Alessio Bellato, Samuele Cortese, Valeria Parlatini
{"title":"Candidate Clinico-Demographic Predictors or Moderators of Efficacy and Tolerability of Pharmacological Treatment in Attention-Deficit/Hyperactivity Disorder (ADHD): An Analysis of the MED-ADHD Repository of Randomised Controlled Trials.","authors":"Sulagna Roy, Guilherme Fusetto Veronesi, Sara Mannarini, Daniele Pirolo, Alessio Bellato, Samuele Cortese, Valeria Parlatini","doi":"10.1007/s40263-026-01323-7","DOIUrl":"10.1007/s40263-026-01323-7","url":null,"abstract":"<p><strong>Background and objective: </strong>Randomised controlled trials (RCTs) have demonstrated that pharmacotherapy reduces symptoms of attention-deficit/hyperactivity disorder (ADHD) at a group level, but efficacy and tolerability vary across individuals. Clinico-demographic characteristics may act as predictors and/or moderators of treatment efficacy and tolerability, but systematic evidence remains limited. Therefore, we systematically analysed RCTs of ADHD medications to identify potential demographic and clinical predictors/moderators of efficacy and tolerability across the lifespan.</p><p><strong>Methods: </strong>Randomised controlled trials were identified from the MED-ADHD database ( https://med-adhd.org/ ), a repository of RCTs of medications for ADHD in children, adolescents and adults. The database is based on systematic searches of multiple electronic sources, including PubMed, BIOSIS Previews, CINAHL, the Cochrane Central Registry of Controlled Trials and EMBASE, and is also complemented by unpublished data obtained from manufacturers and study authors. We used the most recent (2026) version of MED-ADHD. The risk of bias was assessed using the revised Cochrane risk-of-bias tool (RoB 2).</p><p><strong>Results: </strong>Among the 171 RCTs screened, 62 assessed clinico-demographic factors as possible predictors or moderators of treatment efficacy and tolerability. Age was the most examined characteristic (56.4%) followed by, among the top five, psychiatric comorbidities (53.2%), sex (46.8%), baseline ADHD symptom severity (27.4%), and ADHD presentation (24.2%). Most RCTs reported no significant findings although there was preliminary evidence of associations with age (17.7%), psychiatric comorbidities (17.7%), baseline ADHD symptom severity (16.1%), sex (11.3%), and ADHD presentation (4.8%). Risk of bias was rated high in 37% of RCTs.</p><p><strong>Conclusions: </strong>Stringent sample selection and reliance on group-level analyses may limit the power to detect predictors and moderators of treatment efficacy and tolerability in classical RCTs. Consequently, the current evidence provides limited and inconsistent guidance on clinically meaningful predictors/moderators. However, variables such as age, psychiatric comorbidities, sex, baseline severity and ADHD presentation have been the most frequently examined with positive findings and may hold promise. Future research should prioritise individual participant data meta-analyses of RCTs, alongside well-powered analyses of a comprehensive observational dataset, to more robustly investigate these associations and support treatment stratification through predictive models.</p>","PeriodicalId":10508,"journal":{"name":"CNS drugs","volume":" ","pages":"1459-1479"},"PeriodicalIF":7.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study. 裸盖菇素对健康参与者运动功能的影响:一项1期、随机、三盲、剂量发现研究
IF 7 2区 医学
CNS drugs Pub Date : 2026-11-01 Epub Date: 2026-08-07 DOI: 10.1007/s40263-026-01326-4
Chiranth Bhagavan, Olivia Carter, Glenn Nielsen, David Berlowitz, Sara Issak, Sabine Braat, Sophie Zaloumis, Zachary Attard, Gina Oliver, Deanne Mayne, James Rucker, Matthew Butler, Orwa Dandash, Alexander Bryson, Richard A Kanaan
{"title":"Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study.","authors":"Chiranth Bhagavan, Olivia Carter, Glenn Nielsen, David Berlowitz, Sara Issak, Sabine Braat, Sophie Zaloumis, Zachary Attard, Gina Oliver, Deanne Mayne, James Rucker, Matthew Butler, Orwa Dandash, Alexander Bryson, Richard A Kanaan","doi":"10.1007/s40263-026-01326-4","DOIUrl":"10.1007/s40263-026-01326-4","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Psychedelics exert widespread effects on brain activity, but their impact on motor function is unclear. This is clinically relevant given the emerging interest in psychedelic-assisted physical therapy for disorders of motor function. This study examined the feasibility and safety of administering movement tasks following low-to-moderate doses of psilocybin in healthy volunteers.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Healthy adult participants were randomly assigned three psilocybin doses consisting of either (1) 5 mg, 10 mg and 15 mg or (2) 10 mg, 15 mg and 20 mg, with at least 1 week between doses. Movement tasks were administered at 1.5 h, 3 h and 4.5 h post-dose. Participants, physiotherapists and statisticians were blinded to the dosing order. Feasibility was assessed by evaluating completion of the de Morton Mobility Index and Functional Movement Exploration (assessing gross motor function). Safety outcomes included vital signs and adverse events. Additional exploratory motor outcomes included the Action Research Arm Test (assessing upper limb functional performance), Box and Block Test (Original and Modified versions) (combining dexterity with motor speed), Digit Symbol Substitution Test (combining motor speed with intellectual functions) and Reaction Time Ruler Drop Test (assessing reaction time). Alterations in conscious states and blinding efficacy were also assessed. Outcomes were summarised descriptively and with post hoc linear mixed-effects modelling performed to explore dose- and time-related effects.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 13 participants (62% male) were enrolled, with a median age of 33 years (range 22-39 years), median height of 177 cm (155-188 cm) and median weight of 74 kg (51-94 kg). One participant was unable to complete several movement tasks at 20 mg. Nausea (n = 8, 62%) and headache (n = 7, 54%) were the most common adverse events. No serious adverse events or adverse events related to movement task administration occurred. Median values [interquartile ranges] remained near-perfect for the de Morton Mobility Index (92.5-100.0 [85.0-100.0]), Functional Movement Exploration (100.0 [96.0-100.0]) and Action Research Arm Test (56.0-57.0 [52.0-57.0]). Baseline Box and Block Test (Original) median scores (65.0 [60.0-67.0]) improved to 79.0 [70.0-83.0] at 5 mg and 4.5 h post-dose (5 mg-4.5 h), and worsened to 57.5 [51.0-64.0] at 20 mg-1.5 h. Baseline Box and Block Test (Modified) median scores (48.0 [47.0-53.0]) worsened to 43.0 [35.0-45.0] at 20 mg-1.5 h. Baseline Digit Symbol Substitution Test median scores (73.0 [66.0-77.0]) improved to 87.0 [81.0-90.0] at 10 mg-4.5 h, and worsened to 62.0 [54.0-86.0] at 20 mg-1.5 h. Reaction Time Ruler Drop Test scores lacked consistent dose-related changes. Alterations in conscious states were greatest at 20 mg. Participants and physiotherapists correctly guessed the administered dose 53% and 50% of the time, respectively.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion","PeriodicalId":10508,"journal":{"name":"CNS drugs","volume":" ","pages":"1527-1546"},"PeriodicalIF":7.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书